Rein Therapeutics Inc

Research Rein Therapeutics Inc (RNTX) on Bullrun: market cap USD 88.96M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRNTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 88.96M
• Financial periodFY2025
• Net income-USD 49.90M

Valuation Snapshot

latest market cap is USD 88.96M.

About Rein Therapeutics Inc

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.

Frequently asked questions

What is Rein Therapeutics Inc's market cap?

Rein Therapeutics Inc's market capitalization is USD 88.96M.

What does Rein Therapeutics Inc do?

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.